Ultrasound-guided radiofrequency ablation enhances natural killer-mediated antitumor immunity against liver cancer

Mo,Zelai; Lu,Hailan; Mo,Shaowei; Fu,Xiangmin; Chang,Shunwu; Yue,Jie

doi:10.3892/ol.2018.8231

Ultrasound-guided radiofrequency ablation enhances natural killer-mediated antitumor immunity against liver cancer

Authors:
- Zelai Mo
- Hailan Lu
- Shaowei Mo
- Xiangmin Fu
- Shunwu Chang
- Jie Yue
View Affiliations

Affiliations: Department of Ultrasound, The Maternal and Child Health Hospital of Hainan, Haikou, Hainan 570206, P.R. China, Department of Respiratory Medicine, The Hainan General Hospital, Haikou, Hainan 570311, P.R. China, Department of Science and Education, The Hainan General Hospital, Haikou, Hainan 570311, P.R. China, Department of Medical Records, The Hainan General Hospital, Haikou, Hainan 570311, P.R. China, Department of General Surgery, The Maternal and Child Health Hospital of Hainan, Haikou, Hainan 570206, P.R. China, Department of Vascular Surgery, The Maternal and Child Health Hospital of Hainan, Haikou, Hainan 570206, P.R. China
Published online on: March 12, 2018 https://doi.org/10.3892/ol.2018.8231
Pages: 7014-7020
Copyright: © Mo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

For patients with liver cancer who are not sufficiently fit for surgical resection, radiofrequency ablation (RFA) is an effective and low risk treatment modality; however, the mechanism underlying this procedure is not fully understood. In the present study, a series of experiments were conducted, which demonstrated that RFA therapy stimulates innate antitumor immunity via directly enhancing natural killer (NK) cell cytotoxicity, thus achieving a favorable outcome for patients with liver tumors. It was determined that the percentage of NK cells within the peripheral blood of the rabbits in the RFA treatment groups were significantly higher, compared with the control groups. The levels of interferon‑γ and tumor necrosis factor‑α in NK cells were also significantly upregulated following thermal coagulation induced via RFA. In addition, RFA enhanced the NK cell receptor, NK group 2D (NKG2D), expression and NK cell antitumor cytotoxicity in hepatic cancer cells. The results indicated that the RFA treatment could effectively eliminate liver tumors via enhancing NK-mediated antitumor activity and NKG2D expression.

View Figures

View References

1	Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK and Goldstein RM: Hepatocellular carcinoma: Management of an increasingly common problem. Proc (Bayl Univ Med Cent). 21:266–280. 2008. View Article : Google Scholar : PubMed/NCBI
2	Bosch FX, Ribes J, Díaz M and Cléries R: Primary liver cancer: Worldwide incidence and trends. Gastroenterology. 127 5 Suppl 1:S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
3	Simonetti RG, Camma C, Fiorello F, Politi F, D'Amico G and Pagliaro L: Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci. 36:962–972. 1991. View Article : Google Scholar : PubMed/NCBI
4	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
5	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global Cancer Statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
6	Zhou Y, Sui C, Li B, Yin Z, Tan Y, Yang J and Liu Z: Repeat hepatectomy for recurrent hepatocellular carcinoma: A local experience and a systematic review. World J Surg Oncol. 8:552010. View Article : Google Scholar : PubMed/NCBI
7	Lee PH, Lin WJ, Tsang YM, Hu RH, Sheu JC, Lai MY, Hsu HC, May W and Lee CS: Clinical management of recurrent hepatocellular carcinoma. Ann Surg. 222:670–676. 1995. View Article : Google Scholar : PubMed/NCBI
8	Kanematsu T, Matsumata T, Takenaka K, Yoshida Y, Higashi H and Sugimachi K: Clinical management of recurrent hepatocellular carcinoma after primary resection. Br J Surg. 75:203–206. 1988. View Article : Google Scholar : PubMed/NCBI
9	Tsujita E, Yamashita Y, Takeishi K, Matsuyama A, Tsutsui S, Matsuda H, Toshima T, Taketomi A, Shirabe K, Ishida T and Maehara Y: Poor prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma in the modern era. Am Surg. 78:419–425. 2012.PubMed/NCBI
10	Ikeda K, Osaki Y, Nakanishi H, Nasu A, Kawamura Y, Jyoko K, Sano T, Sunagozaka H, Uchino K, Minami Y, et al: Recent progress in radiofrequency ablation therapy for hepatocellular carcinoma. Oncology. 87 Suppl 1:S73–S77. 2014. View Article : Google Scholar
11	Feng K and Ma KS: Value of radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Gastroenterol. 20:5987–5998. 2014. View Article : Google Scholar : PubMed/NCBI
12	Xu Q, Kobayashi S, Ye X and Meng X: Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma: A meta-analysis of 16,103 patients. Sci Rep. 4:72522014. View Article : Google Scholar : PubMed/NCBI
13	Khajanchee YS, Hammill CW, Cassera MA, Wolf RF and Hansen PD: Hepatic resection vs. minimally invasive radiofrequency ablation for the treatment of colorectal liver metastases a markov analysis. Arch Surg. 146:1416–1423. 2011. View Article : Google Scholar : PubMed/NCBI
14	Fu C, Liu N, Deng Q, Li X, Ma K and Bie P: Radiofrequency ablation vs. surgical resection on the treatment of patients with small hepatocellular carcinoma: A system review and meta-analysis of five randomized controlled trials. Hepatogastroenterology. 61:1722–1729. 2014.PubMed/NCBI
15	Nguyen T, Hattery E and Khatri VP: Radiofrequency ablation and breast cancer: A review. Gland Surg. 3:128–135. 2014.PubMed/NCBI
16	van der Ploeg IM, van Esser S, van den Bosch MA, Mali WP, van Diest PJ, Rinkes Borel IH and van Hillegersberg R: Radiofrequency ablation for breast cancer: A review of the literature. Eur J Surg Oncol. 33:673–677. 2007. View Article : Google Scholar : PubMed/NCBI
17	Hiraki T, Gobara H, Iguchi T, Fujiwara H, Matsui Y and Kanazawa S: Radiofrequency ablation as treatment for pulmonary metastasis of colorectal cancer. World J Gastroenterol. 20:988–996. 2014. View Article : Google Scholar : PubMed/NCBI
18	Fegrachi S, Besselink MG, van Santvoort HC, van Hillegersberg R and Molenaar IQ: Radiofrequency ablation for unresectable locally advanced pancreatic cancer: A systematic review. HPB (Oxford). 16:119–123. 2014. View Article : Google Scholar : PubMed/NCBI
19	McGhana JP and Dodd GD: Radiofrequency ablation of the liver: Current status. AJR Am J Roentgenol. 176:3–16. 2001. View Article : Google Scholar : PubMed/NCBI
20	Navarra G, Bartolotta M, Scisca C and Barbera A: Ultrasound-guided radiofrequency-assisted segmental arterioportal vascular occlusion in laparoscopic segmental liver resection. Surg Endosc. 22:1724–1728. 2008. View Article : Google Scholar : PubMed/NCBI
21	Liu CH, Yu CY, Chang WC, Dai MS, Hsiao CW and Chou YC: Radiofrequency ablation of hepatic metastases: Factors influencing local tumor progression. Ann Surg Oncol. 21:3090–3095. 2014. View Article : Google Scholar : PubMed/NCBI
22	Waldhauer I and Steinle A: NK cells and cancer immunosurveillance. Oncogene. 27:5932–5943. 2008. View Article : Google Scholar : PubMed/NCBI
23	Morvan MG and Lanier LL: NK cells and cancer: You can teach innate cells new tricks. Nat Rev Cancer. 16:7–19. 2016. View Article : Google Scholar : PubMed/NCBI
24	Marcus A, Gowen BG, Thompson TW, Iannello A, Ardolino M, Deng W, Wang L, Shifrin N and Raulet DH: Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol. 122:91–128. 2014. View Article : Google Scholar : PubMed/NCBI
25	Hagerling C, Casbon AJ and Werb Z: Balancing the innate immune system in tumor development. Trends Cell Biol. 25:214–220. 2015. View Article : Google Scholar : PubMed/NCBI
26	Moretta A, Marcenaro E, Parolini S, Ferlazzo G and Moretta L: NK cells at the interface between innate and adaptive immunity. Cell Death Differ. 15:226–233. 2008. View Article : Google Scholar : PubMed/NCBI
27	Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM and Ugolini S: Innate or adaptive immunity? The example of natural killer cells. Science. 331:44–49. 2011. View Article : Google Scholar : PubMed/NCBI
28	Vivier E, Nunès JA and Vély F: Natural killer cell signaling pathways. Science. 306:1517–1519. 2004. View Article : Google Scholar : PubMed/NCBI
29	Xuan XY, Zhang JF, Hu GM, Li QR, Liu PP and Du Y: Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma. Cancer Gene Ther. 22:368–374. 2015. View Article : Google Scholar : PubMed/NCBI
30	Raneros Baragaño A, Suarez-Álvarez B and López-Larrea C: Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention. Oncoimmunology. 3:e284972014. View Article : Google Scholar : PubMed/NCBI
31	Spear P, Wu MR, Sentman ML and Sentman CL: NKG2D ligands as therapeutic targets. Cancer Immun. 13:82013.PubMed/NCBI
32	Dromi SA, Walsh MP, Herby S, Traughber B, Xie J, Sharma KV, Sekhar KP, Luk A, Liewehr DJ, Dreher MR, et al: Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity. Radiology. 251:58–66. 2009. View Article : Google Scholar : PubMed/NCBI
33	Zerbini A, Pilli M, Laccabue D, Pelosi G, Molinari A, Negri E, Cerioni S, Fagnoni F, Soliani P, Ferrari C and Missale G: Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology. 138:1931–1942. 2010. View Article : Google Scholar : PubMed/NCBI
34	Virmani S, Harris KR, Szolc-Kowalska B, Paunesku T, Woloschak GE, Lee FT, Lewandowski RJ, Sato KT, Ryu RK, Salem R, et al: Comparison of two different methods for inoculating VX2 tumors in rabbit livers and hind limbs. J Vasc Interv Radiol. 19:931–936. 2008. View Article : Google Scholar : PubMed/NCBI
35	Fischer AH, Jacobson KA, Rose J and Zeller R: Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc. 2008:pdb.prot49862008.PubMed/NCBI
36	Hoppner M, Luhm J, Schlenke P, Koritke P and Frohn C: A flow-cytometry based cytotoxicity assay using stained effector cells in combination with native target cells. J Immunol Methods. 267:157–163. 2002. View Article : Google Scholar : PubMed/NCBI
37	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
38	Seong NJ, Yoon CJ, Kang SG, Chung JW, Kim HC and Park JH: Effects of arsenic trioxide on radiofrequency ablation of VX2 liver tumor: Intraarterial versus intravenous administration. Korean J Radiol. 13:195–201. 2012. View Article : Google Scholar : PubMed/NCBI
39	Ohshima K, Suzumiya J, Shimazaki K, Kato A, Tanaka T, Kanda M and Kikuchi M: Nasal T/NK cell lymphomas commonly express perforin and Fas ligand: Important mediators of tissue damage. Histopathology. 31:444–450. 1997. View Article : Google Scholar : PubMed/NCBI
40	Scheele J, Stangl R and Altendorf-Hofmann A: Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history. Br J Surg. 77:1241–1246. 1990. View Article : Google Scholar : PubMed/NCBI
41	Cucchetti A, Piscaglia F, Cescon M, Ercolani G and Pinna AD: Systematic review of surgical resection vs. radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol. 19:4106–4118. 2013. View Article : Google Scholar : PubMed/NCBI
42	Mulier S, Ni Y, Jamart J, Ruers T, Marchal G and Michel L: Local recurrence after hepatic radiofrequency coagulation: Multivariate meta-analysis and review of contributing factors. Ann Surg. 242:158–171. 2005. View Article : Google Scholar : PubMed/NCBI
43	Pawlik TM, Izzo F, Cohen DS, Morris JS and Curley SA: Combined resection and radiofrequency ablation for advanced hepatic malignancies: Results in 172 patients. Ann Surg Oncol. 10:1059–1069. 2003. View Article : Google Scholar : PubMed/NCBI
44	Gajewski TF, Schreiber H and Fu YX: Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 14:1014–1022. 2013. View Article : Google Scholar : PubMed/NCBI
45	Cheng M, Chen Y, Xiao W, Sun R and Tian Z: NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol. 10:230–252. 2013. View Article : Google Scholar : PubMed/NCBI